Evidence map›Paper›PMID 42499529›Full record

ReviewBioactive materials2026

Emerging bioactive microneedle platforms for disease management: From cutaneous disorders to systemic therapeutics.

Yiming Xiang, Ziya Gong, Juying Liu, Yizhou Zhu, Zhiyong Zhang, Bin Li, Jian Luo, Meiling Su, Kelvin W K Yeung

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yiming XiangHubei Key Laboratory of Medical Information Analysis and Tumor Diagnosis & Treatment, Key Laboratory of Cognitive Science, College of Biomedical Engineering, South-Central Minzu University, Wuhan, 430074, China.
Ziya GongHubei Key Laboratory of Medical Information Analysis and Tumor Diagnosis & Treatment, Key Laboratory of Cognitive Science, College of Biomedical Engineering, South-Central Minzu University, Wuhan, 430074, China.
Juying LiuHubei Key Laboratory of Medical Information Analysis and Tumor Diagnosis & Treatment, Key Laboratory of Cognitive Science, College of Biomedical Engineering, South-Central Minzu University, Wuhan, 430074, China.
Yizhou ZhuDepartment of Orthopaedics & Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, 999077, China.
Zhiyong ZhangTranslational Research Centre of Regenerative Medicine and 3D Printing, Guangdong Province Engineering Research Center for Biomedical Engineering, State Key Laboratory of Respiratory Disease, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510000, China.
Bin LiMedical 3D Printing Center, Orthopedic Institute, Department of Orthopedic Surgery, The First Affiliated Hospital, School of Basic Medical Sciences, Interdisciplinary Innovation Center for Nanomedicine, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College, Soochow University, Suzhou, Jiangsu, 215000, China.
Jian LuoDepartment of Orthopedics, Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), Tongji University School of Medicine, Shanghai, 200233, China.
Meiling SuDepartment of Orthopedics, Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), Tongji University School of Medicine, Shanghai, 200233, China.
Kelvin W K YeungDepartment of Orthopaedics & Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, 999077, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Beyond their conventional role as passive transdermal delivery vehicles, microneedle (MN) platforms now function as active bio-interfaces capable of modulating therapeutic responses in both localized and systemic diseases. This review summarizes recent advances in MN technology, focusing on the transition from traditional matrix-controlled delivery to bioactive microneedles. Although localized applications at barrier surfaces, such as treating cutaneous disorders and mucosal lesions, remain a fundamental focus, this review emphasizes the application of MNs in complex chronic metabolic diseases (e.g., diabetes), oncology (e.g., melanoma and glioblastoma), and deep-tissue degenerative diseases of the cardiovascular, nervous, and musculoskeletal systems. Integrating stimuli-responsive materials, including metal-organic frameworks (MOFs), aggregation-induced emission luminogens (AIEgens), and smart hydrogels, with external physical stimuli enables autonomous, closed-loop interventions, thereby advancing personalized systemic therapy. Furthermore, we summarize recent progress in applying MNs to non-traditional sites and deep-tissue repair. Finally, rather than focusing solely on phenotypic efficacy, we discuss key translational challenges, including manufacturing scalability, biosafety, and regulatory pathways, to guide future clinical translation.

Indexed as

Bioactive microneedlesClinical translationDeep-tissue repairPersonalized systemic medicineStimuli-responsive materials

Identifiers

PMID42499529
PMCPMC13396628

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.